Loading...
Loading...
Analysts at H.C Wainwright initiated coverage on
Onconova Therapeutics IncONTX with a Buy rating.
The target price for Onconova Therapeutics is set to $6.
Onconova Therapeutics shares have dropped 58.91 percent over the past 52 weeks, while the S&P 500 index has surged 13.21 percent in the same period.
Onconova Therapeutics' shares closed at $2.26 yesterday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in